Cargando…

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question

Detalles Bibliográficos
Autores principales:	Ottaiano, Alessandro, Caraglia, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497981/ https://www.ncbi.nlm.nih.gov/pubmed/34631590 http://dx.doi.org/10.3389/fonc.2021.751986

Ejemplares similares

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial
por: Kurreck, Annika, et al.
Publicado: (2022)

Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

Multifaceted Insights into Innovative Approaches to Treating Colorectal Cancer Metastasis: From Emerging Biological Factors to Radiomics
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Opening the Strands of Replication Origins—Still an Open Question
por: Jha, Jyoti K., et al.
Publicado: (2016)

A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
por: Qin, Wan, et al.
Publicado: (2022)

Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4
por: Xu, Qun, et al.
Publicado: (2022)

Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients
por: Wang, Yixing, et al.
Publicado: (2021)

Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy
por: Peng, Yu, et al.
Publicado: (2018)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

The Tumor Dynamism Is the Dark Matter of the NGS Galaxy: How to Understand It?
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

To Stent or Not to Stent in Colorectal Cancer: That is Still the Question in Gastroenterology!
por: Pires, Sara, et al.
Publicado: (2016)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022)

Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
por: Kim, Seijong, et al.
Publicado: (2022)

Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
por: Jiang, Chang, et al.
Publicado: (2018)

Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
por: You, Xia-Hong, et al.
Publicado: (2019)

Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?
por: Negri, Francesca, et al.
Publicado: (2023)

A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The “Border-Time” Bias
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

Control of the Adaptive Immune Response by Tumor Vasculature
por: Mauge, Laetitia, et al.
Publicado: (2014)

Troponin elevation in COVID-19 patients: An important stratification biomarker with still some open questions
por: Maloberti, Alessandro, et al.
Publicado: (2021)

Transcatheter Embolization for Giant Splenic Artery Aneurisms: Still an Open Question
por: Mastroroberto, Marianna, et al.
Publicado: (2012)

Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?
por: Sawicka, Emilia, et al.
Publicado: (2016)

Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
por: Hooglugt, Aukie, et al.
Publicado: (2021)

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
por: Yang, Jieying, et al.
Publicado: (2023)

Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
por: Noonan, Sinead A., et al.
Publicado: (2018)

An Interesting Question in Auscultation
por: Van Peyma, P. W.
Publicado: (1883)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

To scavenge or not to scavenge, that is STILL the question
por: Allan, Elizabeth G., et al.
Publicado: (2013)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

Omega-3 supplementation in autism spectrum disorders: A still open question?
por: Posar, Annio, et al.
Publicado: (2016)

Reading Deficits in Intellectual Disability Are still an Open Question: A Narrative Review
por: Di Blasi, Francesco Domenico, et al.
Publicado: (2018)

Nanodrugs Reprogram Cancer-Associated Fibroblasts and Normalize Tumor Vasculatures for Sequentially Enhancing Photodynamic Therapy of Hepatocellular Carcinoma
por: Fei, Bingyuan, et al.
Publicado: (2023)

The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
por: Lauk, Olivia, et al.
Publicado: (2020)

Tumor histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive?
por: Hanafy, Ehab, et al.
Publicado: (2018)

Interest and Limits of [(18)F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy
por: Jouberton, Elodie, et al.
Publicado: (2021)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a0lis5tnsac3hpd2asdt7jcscs